Tilray Brands Sees 5% Boost in Q2 Cannabis Revenue
International and Canadian sales drive growth; U.S. rescheduling anticipated
Tilray Brands reported a 5% increase in cannabis revenue for its fiscal second quarter, reaching $218 million, driven by strong international medical sales and growth in the Canadian adult-use market.
The company also announced it has achieved a net cash position—meaning more cash on hand than debt—a significant milestone in an industry where most operators carry substantial debt burdens.
CEO Irwin Simon said Tilray is "well-positioned to capitalize on emerging opportunities," particularly anticipated cannabis rescheduling in the United States.
Revenue Drivers
International medical cannabis sales jumped 36% year-over-year, reflecting Tilray's expansion in European markets including Germany and Portugal. The company supplies medical cannabis to patients through partnerships with pharmacies and healthcare systems.
Canadian adult-use cannabis revenue grew 6%, indicating Tilray is gaining market share in the competitive domestic market. The company operates retail stores under the High Park and Chowie Wowie brands, plus wholesale operations selling to other retailers.
Tilray Pharma, the company's pharmaceutical division, also achieved record quarterly revenue—though specific figures weren't disclosed.
Cash Position
Moving to a net cash position gives Tilray more financial flexibility than most cannabis operators. The company can fund expansion, acquisitions, or product development without taking on additional debt or facing pressure from lenders.
This contrasts sharply with many cannabis companies that have restructured debt, diluted shareholders, or sold assets to manage cash flow challenges amid falling prices and slower growth.
Tilray maintained its full-year adjusted EBITDA guidance despite industry headwinds, suggesting confidence in continued performance.
U.S. Opportunities
Tilray currently doesn't operate in the U.S. THC market due to Nasdaq listing rules that prohibit companies from touching federally illegal substances. But cannabis rescheduling could change that.
If marijuana moves to Schedule III, Nasdaq restrictions might ease—allowing Tilray to enter U.S. cannabis through acquisitions or new operations. The company has made clear it's ready to move into the U.S. market if regulatory barriers fall.
For now, Tilray focuses on CBD products in the United States while building its international cannabis business and non-cannabis beverage operations.
This article is based on original reporting by New Cannabis Ventures.
Original Source
This article is based on reporting from New Cannabis Ventures.
Read the original articleOriginal title: "Tilray Brands Reports Q2 Cannabis Revenue Grew 5%"
Related Topics
Related Stories
BusinessPre-Rolls Overtake Flower as Top-Selling Cannabis Product in 2024
Pre-rolls became the largest U.S. cannabis product category in 2024, generating $3.6 billion in revenue with 383 million units sold, surpassing traditional flower for the first time.
BusinessLegal Cannabis Companies Paid $2.24B in Extra Taxes Under 280E in 2025
Legal cannabis operators paid $2.24 billion in excess federal taxes in 2025 due to Section 280E, with some facing effective rates near 70%, according to Whitney Economics analysis.
South Park's Cannabis Arc Reflects Industry's Cultural Shift
South Park's extended Tegridy Farms storyline became an unintentional case study in cannabis industry commercialization, reflecting real tensions between craft culture and corporate consolidation.
More from Dr. Maya Patel, PharmD
View all articles
Survey of 3,500 Patients Shows Medical Cannabis Reduces Prescription Drug Use
Medicare Launches Pilot Covering CBD Products at $500 Per Patient
Michigan Cannabis Market Posts 7.8% Year-Over-Year Decline in March
